Medplus Health Services Limited
Consumer Discretionary›Consumer Services›Retailing›Pharmacy Retail
Key metrics
Price as of 2026-07-17
Sign in for full ratios and TTM. Learn about these metrics →
Share price
NSE closing price from historical market data.
Loading price history…
Statement tables · Consolidated
Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.
Amounts in ₹ Cr · NSE preferred when both exchanges report the same period · tap + to expand rows
Quarterly results
Quarterly · ₹ Cr · tap + rows to expand
| Metric | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,284 Cr | 1,409 Cr | 4,134 Cr | 5,625 Cr | 1,489 Cr | 3,065 Cr | 1,561 Cr | 1,510 Cr | 1,543 Cr | 1,679 Cr | 1,806 Cr | 1,864 Cr |
| Operating expenses (approx.) | 1,204 Cr | 1,323 Cr | 3,857 Cr | 5,231 Cr | 1,386 Cr | 2,826 Cr | 1,416 Cr | 1,357 Cr | 1,397 Cr | 1,513 Cr | 1,629 Cr | 1,675 Cr |
| EBITDA | 81 Cr | 85 Cr | 278 Cr | 394 Cr | 102 Cr | 239 Cr | 145 Cr | 152 Cr | 146 Cr | 166 Cr | 177 Cr | 190 Cr |
| OPM % | 6.3% | 6.0% | 6.7% | 7.0% | 6.9% | 7.8% | 9.3% | 10.1% | 9.4% | 9.9% | 9.8% | 10.2% |
| Other income | 9 Cr | 10 Cr | 30 Cr | 40 Cr | 9 Cr | 20 Cr | 13 Cr | 16 Cr | 15 Cr | 17 Cr | 18 Cr | 21 Cr |
| Interest | 23 Cr | 24 Cr | 71 Cr | 96 Cr | 25 Cr | 50 Cr | 26 Cr | 27 Cr | 27 Cr | 29 Cr | 31 Cr | 33 Cr |
| Depreciation | 52 Cr | 55 Cr | 165 Cr | 224 Cr | 60 Cr | 123 Cr | 62 Cr | 64 Cr | 66 Cr | 69 Cr | 73 Cr | 76 Cr |
| Profit before tax | 5 Cr | 16 Cr | 41 Cr | 73 Cr | 18 Cr | 66 Cr | 57 Cr | 61 Cr | 53 Cr | 69 Cr | 73 Cr | 80 Cr |
| Tax % | 25.5% | 11.6% | 22.8% | 10.7% | 19.4% | 19.1% | 19.0% | 16.0% | 19.8% | 19.5% | 21.1% | 20.4% |
| Net profit | 4 Cr | 15 Cr | 32 Cr | 66 Cr | 14 Cr | 53 Cr | 46 Cr | 51 Cr | 42 Cr | 56 Cr | 58 Cr | 64 Cr |
| EPS (₹) | ₹0.32 | ₹1.22 | ₹2.69 | ₹5.48 | ₹1.20 | ₹4.44 | ₹3.84 | ₹4.32 | ₹3.54 | ₹4.63 | ₹4.82 | ₹5.33 |
Profit & loss (annual)
Annual · last column is TTM · ₹ Cr · tap + to expand
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|
| Sales | 3,779 Cr | 4,558 Cr | 5,625 Cr | 6,136 Cr | 6,892 Cr | Sign in for TTM |
| Operating expenses (approx.) | 3,476 Cr | 4,292 Cr | 5,271 Cr | 5,600 Cr | 6,214 Cr | Sign in for TTM |
| EBITDA | 304 Cr | 266 Cr | 354 Cr | 536 Cr | 679 Cr | Sign in for TTM |
| OPM % | 8.0% | 5.8% | 6.3% | 8.7% | 9.8% | Sign in for TTM |
| Other income | 31 Cr | 46 Cr | 40 Cr | 49 Cr | 71 Cr | Sign in for TTM |
| Interest | 66 Cr | 83 Cr | 96 Cr | 103 Cr | 120 Cr | Sign in for TTM |
| Depreciation | 119 Cr | 182 Cr | 224 Cr | 250 Cr | 283 Cr | Sign in for TTM |
| Profit before tax | 118 Cr | 47 Cr | 73 Cr | 183 Cr | 275 Cr | Sign in for TTM |
| Tax % | 19.7% | -6.2% | 10.7% | 18.0% | 20.2% | Sign in for TTM |
| Net profit | 95 Cr | 50 Cr | 66 Cr | 150 Cr | 220 Cr | Sign in for TTM |
| EPS (₹) | ₹8.55 | ₹4.17 | ₹5.48 | ₹12.57 | ₹18.33 | Sign in for TTM |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | Sign in for TTM |
Trailing twelve months totals and margin rows
Balance sheet
Annual · ₹ Cr · tap + rows to expand
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Equity capital | 24 Cr | 24 Cr | 24 Cr | 24 Cr | 24 Cr |
| Reserves | 0.0000 Cr | 1,467 Cr | 1,553 Cr | 1,716 Cr | 1,951 Cr |
| Borrowings | — | — | — | — | — |
| Other liabilities | 2,570 Cr | 1,306 Cr | 1,427 Cr | 1,620 Cr | 1,958 Cr |
| Total liabilities | 2,594 Cr | 2,797 Cr | 3,005 Cr | 3,360 Cr | 3,933 Cr |
| Fixed assets (net) | — | 288 Cr | 319 Cr | 291 Cr | 318 Cr |
| CWIP | — | 24 Cr | 5 Cr | 13 Cr | 32 Cr |
| Investments | — | 0.03 Cr | 0.0000 Cr | 0.0000 Cr | 0.0000 Cr |
| Other assets | — | 1,481 Cr | 1,568 Cr | 1,844 Cr | 2,069 Cr |
| Total assets | 2,594 Cr | 2,797 Cr | 3,005 Cr | 3,360 Cr | 3,933 Cr |
Cash flows
Annual · ₹ Cr · tap + rows to expand · last column includes FCF
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Cash from operating activity | 170 Cr | 90 Cr | 144 Cr | 540 Cr | 496 Cr |
| Cash from investing | -703 Cr | 429 Cr | -83 Cr | -318 Cr | -128 Cr |
| Cash from financing | 440 Cr | -170 Cr | -198 Cr | -228 Cr | -256 Cr |
| Net cash flow | -93 Cr | 350 Cr | -137 Cr | -5 Cr | 112 Cr |
| Free cash flow (OCF − Capex) | 52 Cr | -79 Cr | 59 Cr | 481 Cr | 373 Cr |
Ratios
Ratios as reported or derived per annual period.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| ROCE % | 772.7% | 5.6% | 8.2% | 16.4% | 20.0% |
| ROE % | 401.5% | 3.3% | 4.2% | 8.6% | 11.1% |
| Debtor days | — | 1 | 1 | — | — |
| Inventory days | — | 16091 | 10986 | 7933 | 5668 |
| Days payable | — | 3659 | 2074 | — | — |
| Cash conversion cycle | — | 12433 | 8913 | 7933 | 5668 |
| Debt / equity | — | — | — | — | 0.00 |
| Current ratio | — | 3.11 | 2.98 | 3.20 | 3.00 |
| Net debt / EBITDA | 0.00 | -0.86 | -0.26 | -0.16 | -0.29 |
Compare with peers
Loading peers…